Parabilis Medicines, Inc. (PBLS)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
39.11 USD
-0.18
(-0.458%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 39.08 -0.03 (-0.030%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:47 a.m. EDT
This is a speculative biotech play with zero income potential and fundamentally broken metrics. The company is burning cash aggressively, evidenced by negative operating cash flow and massive operating losses, while trading at a valuation that defies logic given the lack of revenue. The balance sheet is precarious; despite holding cash, the debt-to-equity ratio is dangerously high, and the market cap is nearly 33 times the trailing twelve-month sales figure, indicating extreme speculation. While the stock recently rallied off its lows, the technicals are fragile, and the statistical forecasting models offer no predictive power due to insufficient historical data. The options market confirms this uncertainty, with heavy positioning at strikes far from the current price, signaling a wait-for-catalyst strategy rather than a conviction trade. For investors seeking capital preservation or sustainable growth, this security is a severe value trap. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.535 |
| Revenue per Share | 0.015 |
| Market Cap | 4,831,385,088 |
| Forward P/E | -17.89 |
| Website | https://parabilismed.com |
As of Aug. 22, 2026, 2:47 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional move. Call open interest is heavily concentrated at the $30 strike, acting as a major floor, while put open interest clusters at $35 and $50, suggesting a wide range of downside protection is being bought. The lack of directional skew in volume versus open interest implies traders are hedging against a binary event (likely clinical trial results) rather than betting on a steady trend.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.23765826 |
| Address1 | 30 Acorn Park Drive |
| All Time High | 41.49 |
| All Time Low | 24.51 |
| Ask | 39.26 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 380,700 |
| Average Daily Volume3 Month | 662,175 |
| Average Volume | 662,175 |
| Average Volume10Days | 380,700 |
| Bid | 39.05 |
| Bid Size | 2 |
| Book Value | 8.482 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.11 |
| Current Ratio | 17.909 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 40.02 |
| Day Low | 38.5 |
| Debt To Equity | 4.535 |
| Display Name | Parabilis Medicines |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -169,114,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -22.223 |
| Enterprise To Revenue | 25,393.242 |
| Enterprise Value | 3,758,200,064 |
| Eps Current Year | -2.57667 |
| Eps Forward | -2.18667 |
| Eps Trailing Twelve Months | -1.87 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 32.8356 |
| Fifty Day Average Change | 6.274399 |
| Fifty Day Average Change Percent | 0.19108523 |
| Fifty Two Week Change Percent | 23.765827 |
| Fifty Two Week High | 41.49 |
| Fifty Two Week High Change | -2.380001 |
| Fifty Two Week High Change Percent | -0.057363242 |
| Fifty Two Week Low | 24.51 |
| Fifty Two Week Low Change | 14.6 |
| Fifty Two Week Low Change Percent | 0.59567523 |
| Fifty Two Week Range | 24.51 - 41.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,781,098,200,000 |
| Float Shares | 82,074,249 |
| Forward Eps | -2.18667 |
| Forward P E | -17.885643 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Fullday Change | -0.18 |
| Fullday Change Percent | -0.458133 |
| Fullday Price | 39.08 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -12,951,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07027 |
| Held Percent Institutions | 0.81768996 |
| Implied Shares Outstanding | 123,533,240 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-06-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts. |
| Long Name | Parabilis Medicines, Inc. |
| Market | us_market |
| Market Cap | 4,831,385,088 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_316822253 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -231,667,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,854,856,332 |
| Number Of Analyst Opinions | 4 |
| Open | 38.96 |
| Operating Cashflow | -111,291,000 |
| Operating Margins | -343.82434 |
| Payout Ratio | 0.0 |
| Phone | (617) 945-9510 |
| Post Market Change | -0.02999878 |
| Post Market Change Percent | -0.0767036 |
| Post Market Price | 39.08 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 39.29 |
| Price Eps Current Year | -15.178506 |
| Price Hint | 2 |
| Price To Book | 4.610941 |
| Price To Sales Trailing12 Months | 32,644.494 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.834 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.18 |
| Regular Market Change Percent | -0.458133 |
| Regular Market Day High | 40.02 |
| Regular Market Day Low | 38.5 |
| Regular Market Day Range | 38.5 - 40.02 |
| Regular Market Open | 38.96 |
| Regular Market Previous Close | 39.29 |
| Regular Market Price | 39.11 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 316,225 |
| Revenue Per Share | 0.015 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 121,952,030 |
| Shares Percent Shares Out | 0.042600002 |
| Shares Short | 5,257,000 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,954,390 |
| Short Name | Parabilis Medicines, Inc. |
| Short Percent Of Float | 0.0431 |
| Short Ratio | 13.68 |
| Source Interval | 15 |
| State | MA |
| Symbol | PBLS |
| Target High Price | 45.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 41.75 |
| Target Median Price | 41.0 |
| Total Cash | 1,120,696,960 |
| Total Cash Per Share | 9.072 |
| Total Debt | 47,512,000 |
| Total Revenue | 148,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.29607 |
| Two Hundred Day Average Change | 6.8139305 |
| Two Hundred Day Average Change Percent | 0.21098328 |
| Type Disp | Equity |
| Volume | 316,225 |
| Website | https://parabilismed.com |
| Zip | 2,140 |